Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas
Kidney cancers comprise about 3% of all new malignancies in the United States. Renal cell carcinomas (RCCs) are the most common type of renal malignancy making up about 85% of kidney cancer cases. Signs and symptoms of renal cell carcinomas can result from local tumor growth, paraneoplastic syndrome...
Saved in:
Main Author: | Robert Roskoski, Jr (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
by: Robert Roskoski, Jr
Published: (2023) -
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
by: Robert Roskoski, Jr
Published: (2024) -
Rule of five violations among the FDA-approved small molecule protein kinase inhibitors
by: Robert Roskoski, Jr
Published: (2023) -
Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States
by: Robert Roskoski Jr
Published: (2023) -
Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab
by: Maciej Niewada, et al.
Published: (2023)